Clinical Trials Arena on MSN19h
Blue Earth’s radioligand therapy achieves high tumour radiation absorption
Results from the company’s Phase I/II trial showed the injectable therapy to have an effective half-life of 91.4 hours.
Renal & Urology News1d
Enzalutamide vs ADT Slows Sexual Decline in Men With Prostate Cancer BCR
Sexual function data support enzalutamide use in men with high-risk biochemically recurrent (BCR) prostate cancer.
Targeted Oncology1d
Novel rhPSMA Therapy Targets Advanced Prostate Cancer With Precision
Lu rhPSMA-10.1 showed high tumor radiation with low healthy tissue exposure in a phase 1/2 trial for metastatic ...
CURE1d
Xtandi and Talzenna Therapy Shows Responses in Advanced Prostate Cancer
Dr. Chandler Park sat down for an interview with CURE® to discuss the biggest takeaway from the 2025 ASCO GU Symposium in ...
Exercise key to improving sexual dysfunction for patients with prostate cancer, study says
New research from Edith Cowan University (ECU) has confirmed that erectile dysfunction in patients living with prostate ...
Cancer Research3d
About the Journal
Cancer Discovery publishes high-impact articles featuring major advances in research and clinical trials. Topics span the spectrum of cancer research and medicine from the laboratory to the clinic to ...